IHS Chemical Week

Regions :: North America

Novartis to acquire biotech company CoStim Pharmaceuticals

2:33 AM MST | February 17, 2014 | Natasha Alperowicz

Novartis announced today that it is buying CoStim Pharmaceuticals (Cambridge, MA), a privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer. The acquisition will broaden Novartis’s cancer immunotherapy research program, the company says.  Financial terms were not disclosed.   With this acquisition Novartis, already leading in cancer immunotherapy, with investigative chimeric antigen receptor (CAR) technology being developed in collaboration with the University of...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa